Sugemalimab (suge), a newly developed fully human monoclonal antibody against PD-L1, in combination with pemetrexed plus carboplatin for non-squamous (NSQ) NSCLC and in combination with paclitaxel plus carboplatin for squamous (SQ) NSCLC, exhibiting exciting clinical benefit and acceptable safety profile (4), was approved in China for the first-line treatment of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) negative metastatic NSQ and SQ NSCLC (5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.